ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Grants Priority Review Designation for HTX-011
January 03, 2019Heron Therapeutics announced the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for Heron's investigational agent, HTX-011, and has granted it a Priority Review designation..... -
Ultrarestrictive Opioid Rx Protocol Cuts Postoperative Opioid Use
December 10, 2018An ultrarestrictive opioid prescription protocol (UROPP) can reduce the number of opioids prescribed to patients after gynecologic and abdominal surgery.... -
HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDA
June 27, 2018Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs
Pharma Sources Insight January 2025
